LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Novel Culture Medium Developed for Pathogenic Free-Living Amoeba

By LabMedica International staff writers
Posted on 19 Aug 2015
Image: Photomicrograph of the Balamuthia mandrillaris trophozoite in culture (Photo courtesy of the CDC - US Centers of Disease Control and Prevention).
Image: Photomicrograph of the Balamuthia mandrillaris trophozoite in culture (Photo courtesy of the CDC - US Centers of Disease Control and Prevention).
Image: Histopathology of brain tissue showing a cyst of Balamuthia mandrillaris (Photo courtesy of the University of Kentucky Hospital).
Image: Histopathology of brain tissue showing a cyst of Balamuthia mandrillaris (Photo courtesy of the University of Kentucky Hospital).
Balamuthia mandrillaris is an opportunistic protist pathogen and the causative agent of necrotizing hemorrhagic granulomatous encephalitis among other infections, with an estimated fatality rate approaching 98%.

B. mandrillaris, unlike most of other free-living amoebae, does not feed on Gram-negative bacteria and therefore the use of non-nutrient agar coated with bacterial cultures has resulted to be ineffective for its growth. Other special medium have been recommended, but they have some disadvantages, as they require many components and their preparations are laborious.

Microbiologists at the Sonora Technological Institute (Mexico) developed an easy-to-prepare culture medium for axenic growth of B. mandrillaris using Cerva's medium as basal component. Ten strains of B. mandrillaris including a well-characterized US Centers for Disease and Prevention (CDC; Atlanta, GA, USA) reference stain and nine environmental isolates from water and soil were used during the study.

Each one of the 11 components of BM-3 culture medium was combined with Cerva's medium as basal culture medium. The cultures were observed daily for a four-week period under an inverted microscope Axiovert 135 (Zeiss; Gottingen, Germany). The number of trophozoites/mL was determined using a hemocytometer, and the doubling time was calculated by linear regression. The yields in each culture were determined at the end of the logarithmic growth phase.

After the first week of daily observations of the tested combinations of BM-3 components and Cerva's medium, amoebae numbers diminished in every flask. At the end of the second week of incubation, neither trophozoites nor cysts were seen in any modification, except for the one consisting of the basal medium complemented with 10× Hank's balanced salt solution (34.0 mL/500 mL) where growth was recovered. Hank's balanced salt solution was the only one that supported confluent growth of B. mandrillaris and where cell shape and motility of trophozoites were normal.

The authors concluded that nutrimental necessity of B. mandrillaris depends on adequate salt solution, protein extracts, and other nutrients obtained from the fetal bovine serum. When using axenic cultures, the development of a cheaper and easy-to-prepare medium for B. mandrillaris opens the possibility of increasing our knowledge on this lethal pathogen. (The study was published in the August 2015 issue of the journal Diagnostic Microbiology and Infectious Disease.

Related Links:

Sonora Technological Institute 
Zeiss 


Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Rapid Molecular Testing Device
FlashDetect Flash10
Gold Member
Hematology Analyzer
Medonic M32B

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more